Editorials in 2015

Filter By:

Article Type
Year

  • Here's hoping that a proposed shakeup of US regulations will mean that new biotech products avoid AquaAdvantage salmon's two-decade upstream struggle to regulatory approval.

    Editorial

  • And the 2015 Nobel Prize for Pharmacoeconomics goes to.... Martin Shkreli

    Editorial

  • Smear campaigns against those speaking out against scaremongering on genetically modified (GM) crops highlight why support for scientists involved in public outreach is so important.

    Editorial

  • Maximizing the clinical impact of immune profiling will require dedicated immune monitoring facilities and community standards for handling patient samples.

    Editorial

  • Even if human research and clinical practice find a way to integrate personal health data, uptake will remain limited unless people are incentivized to participate.

    Editorial

  • No matter where you look in biopharmaceutical boardrooms, gender bias is evident. Is it so difficult to actually acknowledge this pernicious bias and actively discourage all-male boards?

    Editorial

  • The time has come to systematically assess the pros and cons of different mouse models as predictors of patient responses to cancer therapies.

    Editorial

  • The Apple ResearchKit, the latest effort to bring deep phenotyping to the masses, heralds the arrival of large-scale human population research.

    Editorial

  • Nature Biotechnology supports recent calls for public engagement concerning the risks and benefits of genome editing in the human germline, particularly given our poor knowledge of what we should change in the human genome.

    Editorial

  • Nature Biotechnology is reevaluating editorial oversight of papers centered on computational analyses in anticipation of the 'big data' world.

    Editorial

  • Nature Biotechnology, together with Nature and its sister journals, is now offering anonymity to authors during the peer-review process.

    Editorial

  • European politicians' decision to kick the can of genetically modified (GM) crop approvals down to national governments may accelerate adoption in the short term, but foreshadows legal battles down the road.

    Editorial

  • Despite recent progress, only a fraction of the drug industry's shelved compounds are shared with the research community. Could online collaborative research offer a solution?

    Editorial